Product Name :
DRAK2 (I286) Peptide Applications :
Blocking Background :
DAP (death associated protein) kinase and ZIP kinase are members of a novel protein kinase family, the members of which have the capacity to mediate apoptosis through their catalytic activities. DAP kinase contains a “death domain” and has been shown to mediate γ interferon-induced apoptosis. The introduction of DAP kinase into highly metastatic carcinoma clones lacking DAP kinase expression was shown to result in the suppression of metastasis, thus linking suppression of apoptosis to metastasis. ZIP kinase contains a leucine zipper domain, which is necessary for homodimerization and for interaction with other leucine zipper proteins. ZIP kinase dimerizes with ATF-4, an ATF/CREB transcription factor family member that contains a leucine zipper. DRAK1 (DAP kinase-related apoptosis-inducing protein kinase 1) and DRAK2 are DAP kinase related proteins. Alternative Name :
DAP kinase related apoptosis inducing protein; DAP kinase related apoptosis inducing protein kinase 2; DAP kinase-related apoptosis-inducing protein kinase 2; Death associated protein kinase related 2; DRAK 2; DRAK2; Serine/threonine kinase 17b; Serine/threonine kinase 17b apoptosis inducing; Serine/threonine protein kinase 17B; Serine/threonine-protein kinase 17B; ST17B; STK 17B; Stk17b; Swiss-Prot :
O94768 Product :
1 mg/ml in DI water. Purification&Purity :
Synthetic peptide DRAK2 (I286). (Note: the amino acid sequence is proprietary). The purity is > 98%. Storage&Stability :
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles. Specificity :
This peptide can be used with studies using BS9183 DRAK2 (I286) pAb.

• 

Blocking peptide available as BS9183PP